Endoscopic ultrasonography and pancreatic cancer

T. B. Gardner, Suresh T Chari

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Despite extensive multidisciplinary efforts, the five-year survival rate for all patients with pancreatic adenocarcinoma remains less than 3%. In the last twenty years, endoscopic ultrasound (EUS) has developed into an indispensable tool for the diagnosis and staging of malignant pancreatic lesions. EUS, in combination with helical and multidetector computed tomography scans, is currently 80-90% accurate in determining the tumor TNM stage. EUS fine-needle aspiration obtains diagnostic pathologic samples in approximately 80% of cases, and intraductal ultrasound has augmented the ability to determine the malignant potential of pancreatic strictures. In patients at high-risk for pancreatic malignancy, EUS has been advocated as a screening tool for malignancy. Finally, exciting new developments suggest the potential of EUS as a therapeutic tool, both for the management of pain from pancreatic cancer and as a novel therapeutic-delivery device.

Original languageEnglish (US)
Pages (from-to)161-176
Number of pages16
JournalMinerva Gastroenterologica e Dietologica
Volume54
Issue number2
StatePublished - Jun 2008

Fingerprint

Endosonography
Pancreatic Neoplasms
Neoplasms
Multidetector Computed Tomography
Spiral Computed Tomography
Pain Management
Fine Needle Biopsy
Pathologic Constriction
Adenocarcinoma
Survival Rate
Equipment and Supplies
Therapeutics

Keywords

  • Endosonography
  • Pain
  • Pancreatic neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopic ultrasonography and pancreatic cancer. / Gardner, T. B.; Chari, Suresh T.

In: Minerva Gastroenterologica e Dietologica, Vol. 54, No. 2, 06.2008, p. 161-176.

Research output: Contribution to journalArticle

@article{d1d9e77b83344a17b9633d89fd1be309,
title = "Endoscopic ultrasonography and pancreatic cancer",
abstract = "Despite extensive multidisciplinary efforts, the five-year survival rate for all patients with pancreatic adenocarcinoma remains less than 3{\%}. In the last twenty years, endoscopic ultrasound (EUS) has developed into an indispensable tool for the diagnosis and staging of malignant pancreatic lesions. EUS, in combination with helical and multidetector computed tomography scans, is currently 80-90{\%} accurate in determining the tumor TNM stage. EUS fine-needle aspiration obtains diagnostic pathologic samples in approximately 80{\%} of cases, and intraductal ultrasound has augmented the ability to determine the malignant potential of pancreatic strictures. In patients at high-risk for pancreatic malignancy, EUS has been advocated as a screening tool for malignancy. Finally, exciting new developments suggest the potential of EUS as a therapeutic tool, both for the management of pain from pancreatic cancer and as a novel therapeutic-delivery device.",
keywords = "Endosonography, Pain, Pancreatic neoplasms",
author = "Gardner, {T. B.} and Chari, {Suresh T}",
year = "2008",
month = "6",
language = "English (US)",
volume = "54",
pages = "161--176",
journal = "Minerva Gastroenterologica",
issn = "0026-4776",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Endoscopic ultrasonography and pancreatic cancer

AU - Gardner, T. B.

AU - Chari, Suresh T

PY - 2008/6

Y1 - 2008/6

N2 - Despite extensive multidisciplinary efforts, the five-year survival rate for all patients with pancreatic adenocarcinoma remains less than 3%. In the last twenty years, endoscopic ultrasound (EUS) has developed into an indispensable tool for the diagnosis and staging of malignant pancreatic lesions. EUS, in combination with helical and multidetector computed tomography scans, is currently 80-90% accurate in determining the tumor TNM stage. EUS fine-needle aspiration obtains diagnostic pathologic samples in approximately 80% of cases, and intraductal ultrasound has augmented the ability to determine the malignant potential of pancreatic strictures. In patients at high-risk for pancreatic malignancy, EUS has been advocated as a screening tool for malignancy. Finally, exciting new developments suggest the potential of EUS as a therapeutic tool, both for the management of pain from pancreatic cancer and as a novel therapeutic-delivery device.

AB - Despite extensive multidisciplinary efforts, the five-year survival rate for all patients with pancreatic adenocarcinoma remains less than 3%. In the last twenty years, endoscopic ultrasound (EUS) has developed into an indispensable tool for the diagnosis and staging of malignant pancreatic lesions. EUS, in combination with helical and multidetector computed tomography scans, is currently 80-90% accurate in determining the tumor TNM stage. EUS fine-needle aspiration obtains diagnostic pathologic samples in approximately 80% of cases, and intraductal ultrasound has augmented the ability to determine the malignant potential of pancreatic strictures. In patients at high-risk for pancreatic malignancy, EUS has been advocated as a screening tool for malignancy. Finally, exciting new developments suggest the potential of EUS as a therapeutic tool, both for the management of pain from pancreatic cancer and as a novel therapeutic-delivery device.

KW - Endosonography

KW - Pain

KW - Pancreatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=44349150007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349150007&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 161

EP - 176

JO - Minerva Gastroenterologica

JF - Minerva Gastroenterologica

SN - 0026-4776

IS - 2

ER -